FibroBiologics Achieves 3-Fold IL1B Reduction, 4-Fold IL10 Rise in Burn Study
Daily topical treatments with human dermal fibroblast spheroids over eight days in burn-injured mice eliminated the prominent red inflammatory border across multiple strains and both sexes. Biomarker analysis revealed a 3-fold reduction in IL1B, 4-fold increase in IL10 and downward trends in Col1a1, Col3a1, Mmp1a, Mmp8 and Acta2.
1. Preclinical Study Design
FibroBiologics applied daily topical doses of human dermal fibroblast spheroids to burn wounds in mice, initiating treatment two hours post-injury and continuing for eight consecutive days to assess anti-inflammatory and anti-scarring potential.
2. Visible Healing Outcomes
By day eight, treated wounds displayed the absence of the red inflammatory border seen in control animals, with consistent responses across multiple mouse strains and in both male and female subjects.
3. Molecular and Cellular Biomarkers
Treated tissue showed approximately a 3-fold decrease in pro-inflammatory IL1B and a 4-fold increase in anti-inflammatory IL10. Gene expression trends for collagen synthesis markers (Col1a1, Col3a1), ECM turnover enzymes (Mmp1a, Mmp8) and myofibroblast activation (Acta2) all declined, while an upward trend in Arg1 suggests M2 macrophage polarization.
4. Pipeline Implications
These findings validate FibroBiologics’ strategy to extend its fibroblast-based platform into burn care, supporting future clinical development plans and potential expansion of its wound-healing pipeline.